Prognostic Value of CD133 and SOX2 in Advanced Cancer

Abstract

Background The prognostic value of CD133 and SOX2 expression in advanced cancer remains unclear. This study was first conducted to investigate the association between CD133 or SOX2 positivity and clinical outcomes for advanced cancer patients. Methods Hazard ratios (HRs) with 95% confidence intervals (95% CIs) were calculated to evaluate the correlation between CD133 or SOX2 positivity and overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), cancer-specific survival (CSS), or recurrence-free survival (RFS) from multivariable analysis. Trial sequential analysis (TSA) was also performed. Results 13 studies with 1358 cases (CD133) and five studies with 433 cases (SOX2) were identified. CD133 positivity was correlated with worse CSS and OS, but there was no correlation between CD133 positivity and DFS. SOX2 positivity was associated with poor DFS and RFS but was not linked to PFS. Stratified analysis by study source showed that only CD133 positivity can decrease OS for Chinese patients. Stratified analysis by treatment regimens indicated that CD133 positivity was linked to poor OS in patients treated with adjuvant therapy. TSA showed that additional studies were necessary. Conclusions CD133 and SOX2 might be associated with worse prognosis in advanced cancer. More prospective studies are strongly needed. Impact CD133 and SOX2 may be promising targeted molecular therapy for advanced cancer patients.

Clinical and Prognostic Significance of CD117 in Non-Small Cell Lung Cancer: A Systemic Meta-Analysis

“…Cancer stem cells (CSCs) are a special subpopulation of cancer cells, which are responsible for the major capabilities of self-renewal and uncontrolled proliferation and dif-ferentiation, and increasing evidence suggests that CSCs contribute to cancer metastasis, a worse prognosis, and resistance to chemotherapy or radiation therapy [5][6][7]. Cluster of differentiation 117 (CD117), termed c-kit proto-oncogene, encoded by the c-kit gene, and located on human chromosome 4q11-12, belongs to a type-III transmembrane receptor tyrosine kinase [8,9].…”

A meta-analysis and The Cancer Genome Atlas data of prostate cancer risk and prognosis using epithelial cell adhesion molecule (EpCAM) expression

“…Cancer stem cells (CSCs) are a small group of cells within tumors and are responsible for self-renewal, uncontrolled differentiation, and tumorigenicity [6, 7]. CSCs contribute to cancer development, progression, and metastasis [8–10]. Epithelial cell adhesion molecule (EpCAM), known as epithelial-specific antigen (ESA) or CD326, a membrane glycoprotein, plays an important role in Ca2+ independent hemophilic cell-to-cell adhesion, cell signaling, migration, proliferation, and differentiation [11, 12].…”

Deregulation of extracellular matrix modeling with molecular prognostic markers revealed by transcriptome sequencing and validations in Oral Tongue squamous cell carcinoma

“…MYO1B, a motor protein involve in cellular motility 54 , is known to be overexpressed in HNSCC 55 and is found to play a pivotal role in lymph node metastasis by way of augmenting cancer cell motility 56 . SOX2 is a transcription factor and stem cell marker, known to be expressed in several cancers, playing a major role in cell proliferation, metastasis 57 , tumor drug resistance 58 and is hence a valuable therapeutic target 59 . SOX2 maintains the stemness of CSC, ultimately resulting in cancer relapse and resistance to treatment 60 .…”